Latest R207910 Stories
In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time.
SEATTLE, June 17 /PRNewswire/ -- When: Wednesday, June 17, 2009, 10:30am Eastern (9:30am Central; 8:30am Mountain; 7:30am Pacific) Dial-in: 1-877-879-6184 (toll-free) 1-719-325-4759 (local access) Conference Title: TB Alliance/Tibotec Briefing Participant passcode: 2895940 Where: Pacific Health Summit Bell Harbor International Conference Center Pacific Board Room Seattle,...
Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis SEATTLE, June 17 /PRNewswire/ -- A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced today at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to...
Clinical Activity Of TMC207 shows ATP-Synthase is a Viable Target for treatment of TB MECHELEN, Belgium, June 3 /PRNewswire/ -- Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today.
Tuberculosis drug shows promise against latent bacteria WASHINGTON, Sept.
- A trick or prank.